47 results about "Pms premenstrual syndrome" patented technology

A progesterone receptor modulator of the structure is provided. Use of compositions containing this compound for contraception, hormone replacement therapy, treating hormone-dependent disease, synchronizing estrus, treating dysmenorrhea, treating dysfunctional uterine bleeding, inducing amenorrhea, or treating symptoms of premenstrual syndrome and premenstrual dysphoric disorder in a mammal are described.

Food products fortified with a therapeutically effective amount of milk mineral are administered for the treatment of high blood pressure, stroke, obesity, kidney stones, colon cancer, breast cancer, head and neck tumors, premenstrual syndrome, postpartum depression, hypertensive disorders of pregnancy, Type-2 diabetes, depression, asthma, inflammatory bowel disease, attention deficit disorder, migraine headaches, kidney disease, hypercholesterolaemia, congestive heart failure, or immune deficiency.

The present compounds are intermediates for the preparation of quinoline derivatives and compositions having gonadotropin-releasing hormone antagonistic activity useful as propylactics or therapeutic agent for the prevention or treatment of several hormone dependent diseases, for example, a sex hormone dependent cancer (e.g. prostatic cancer, uterine or cervical cancer, breast cancer, pituitary adenoma), benign prostatic hypertrophy, myoma of the uterus, endometriosis, precocious puberty, amenorrhea, premenstrual syndrome, polycystic ovary syndrome and acne vulgaris; are effective as a fertility controlling agent in both sexes (e.g. a pregnancy controlling agent and a menstrual cycle controlling agent); can be used as a male or female contraceptive, as an ovulation-inducing agent; can be used as an infertility treating agent by using a rebound effect owing to a stoppage of administration thereof; and are useful for modulating estrous cycles in animals in the field of animal husbandry, as agents for improving the quality of edible meat or promoting the growth of animals, and as agents for promoting spawning in fish.

The invention pertains to a composition and a method for the treatment of mood disorders, in particular of treating, preventing or alleviate depression, mood disorders or insufficient mood, obesity, overweight, premenstrual syndrome, craving, carbohydrate craving, chocolate craving, menopausal complaints, erectile dysfunction and / or reduced libido. The composition contains cocoa or one or more of its pharmacologically active components, and a dopamine D2 receptor agonist.

The present invention relates to a pharmaceutical composition for treating, for example, a disorder or condition selected from the group consisting of hypertension, depression, generalized anxiety disorder, phobias, posttraumatic stress disorder, avoidant personality disorder, sexual dysfunction, eating disorders, obesity, chemical dependencies, cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders, Parkinson's diseases, endocrine disorders, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of schizophrenia, premenstrual syndrome, Fibromyalgia Syndrome, stress incontinence, Tourette syndrome, trichotillomania, kleptomania, male impotence, cancer, chronic paroxysmal hemicrania and headache in a mammal, preferably a human, comprising (i) an atypical antipsychotic or a pharmaceutically acceptable salt thereof, (ii) a 5-HT1B receptor antagonist or a pharmaceutically acceptable salt thereof, wherein the 5-HT1B receptor antagonist is selected from the group consisting of (A) a compound of the formula I as described in the specification and (B) a compound of the formula II as described in the specification, and optionally (iii) a pharmaceutically acceptable carrier.

A composition is provided which contains policosanol and chromium and / or chromium salts and which may be used for treating, preventing and or reducing metabolic syndrome, hypercholesterolemia and hypoglycemia related diseases, total cholesterol, LDL-cholesterol, LDL / HDL ratio, triglycerides, coronary heart disease (heart attacks and strokes), inflammation, deep-vein thrombosis, immunoregulatory diseases, cardiovascular diseases, obesity, insulin resistance, dyslipidemia, raised blood pressure, fatigue, premenstrual syndrome, anxiety, depression and / or neurodegenerative disorders, and / or raising HDL cholesterol and / or lean body mass in humans and animals. The method comprises administering policosanol and chromium and / or chromium salts which together effectively lower blood glucose levels and lower the LDL / HDL cholesterol ratio. Typically, the administered composition includes about 0.1-10:1 parts by weight of policosanol to chromium and / or chromium salts.

A gonadotropin-releasing hormone antagonistic composition, which comprises an optionally substituted condensed-bicyclic compound consisting of a homo or hetero 5 to 7 membered ring and a homo or hetero 5 to 7 membered ring is effective as a propylactic or therapeutic agent for the prevention or treatment of several hormone dependent diseases, for example, a sex hormone dependent cancer (e.g. prostatic cancer, cancer of uterine cervix, breast cancer, pituitary adenoma), benign prostatic hypertrophy, myoma of the uterus, endometriosis, precocious puberty, amenorrhea, premenstrual syndrome, polycystic ovary syndrome and acne vulgaris; is effective as a fertility controlling agent in both sexes (e.g. a pregnancy controlling agent and a menstrual cycle controlling agent); can be used as a contraceptive of male or female, as an ovulation-inducing agent of female; can be used as an infertility treating agent by using a rebound effect owing to a stoppage of administration thereof; is useful as modulating estrous cycles in animals in the field of animal husbandry, as an agent fro improving the quality of edible meat or promoting the growth of animals; is useful as an agent of spawning promotion in fish.

A bolus dose supplement, foodstuff, beverage and beverage concentrate with calcium and vitamin D for the treatment and prevention of PMS, panic attacks, and postpartum depression. The combination of adequate calcium and vitamin D is provided as a multi-vitamin and mineral supplement. The bolus dose is comprised of 2 main ingredients calcium and vitamin D at 1000-1500 mg of elemental calcium in the form of carbonate or citrate or gluconate or citrate maleate and 400-20,000 I.U. of parent vitamin D

The invention relates to new crystalline modifications of the hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine, crystalline modification of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride which are suitable in particular for the preparation of solid medicaments for the treatment or prevention of depressive disorders, anxiety disorders, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, fibromyalgia, sleeping disorders, psychiatric disorders, cerebral infarct, tension, for the therapy of side-effects in the treatment of hypertension, cerebral disorders, chronic pain, acromegaly, hypogonadism, secondary amenorrhea, premenstrual syndrome and undesired puerperal lactation.

One aspect of the present invention relates to heterocyclic compounds that are ligands for nicotinic acetylcholine receptors. A second aspect of the invention relates to the use of a compound of the invention for modulation of a mammalian nicotinic acetylcholine receptor. The present invention also relates to the use of a compound of the invention for treating a mammal suffering from Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, obesity, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, disorders of sleep, autism, mutism or trichtillomania.

A yeast extract or yeast-derived bioactive peptide having an activity of selectively inhibiting reuptake of serotonin and norepinephrine, which can be effectively used in preventing or treating various diseases related to reuptake of serotonin and norepinephrine, especially depression, anxiety, stress, fatigue and obesity are provided. Also, a yeast extract or yeast-derived bioactive peptide having activities as an anti-stress agent, an anti-fatigue agent, premenstrual syndrome (PMS) and menstrual pain relaxants, and a brain-neurotrophic factor, and a method for preparing the bioactive peptide are provided. The yeast extract or yeast-derived bioactive peptide is effective in relieving stress, nervousness, anxiety, tension, insomnia, fatigue, and imbalance in the autonomic nerve regulation. Therefore, the yeast extract or yeast-derived bioactive peptide is vailable as an anti-depression agent, an anti-anxiety agent, an anti-stress agent, an anti-fatigue agent, an anti-obesity agent, premenstrual syndrome and menstrual pain relaxants, a bain-neurotrophin, and a source of active foods having these activities.

One aspect of the present invention relates to heterocyclic compounds that are ligands for nicotinic acetylcholine receptors. A second aspect of the invention relates to the use of a compound of the invention for modulation of a mammalian nicotinic acetylcholine receptor. The present invention also relates to the use of a compound of the invention for treating a mammal suffering from Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, obesity, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, disorders of sleep, autism, mutism or trichtillomania.

A composition is provided which contains policosanol and biotin and which may be used for treating, preventing and or reducing metabolic syndrome, hypercholesterolemia and hypoglycemia related diseases, total cholesterol, LDL-cholesterol, LDL / HDL ratio, triglycerides, coronary heart disease (heart attacks and strokes), inflammation, deep-vein thrombosis, immunoregulatory diseases, cardiovascular diseases, obesity, insulin resistance, dyslipidemia, raised blood pressure, fatigue, premenstrual syndrome, anxiety, depression and / or neurodegenerative disorders, and / or raising HDL cholesterol in humans and animals. The method comprises administering policosanol and biotin which together effectively lower blood glucose levels and lower the LDL / HDL cholesterol ratio. Typically, the administered composition includes about 0.1-10:1 parts by weight of policosanol to biotin.

Two extracts VT-1 and VT-2 of shrub chastetree fruit for treating periodic mastodynia, menalgia and premenstrual syndrome is prepared through extracting in mixture of water and methanol or ethanol, separating by adsorptive resin to remove impurities, and eluting by the aqueous solution of alcohol with different concentrations.

Spiroindoline derivatives, process for their preparation and pharmaceutical compositions thereof, their use for the treatment and / or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and / or prophylaxis of diseases, especially sex-hormone-related diseases in both men and women, in particularly those selected from the group of endometriosis, uterine fibroids, polycystic ovarian disease, hirsutism, precocious puberty, gonadal steroid-dependent neoplasia such as cancers of the prostate, breast and ovary, gonadotrope pituitary adenomas, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hypertrophy, contraception and infertility (e.g., assisted reproductive therapy such as in vitro fertilization). The present application relates in particular to spiroindoline derivatives as gonadotropin-releasing hormone (GnRH) receptor antagonists.

The present specification relates to a composition which contains ginseng berry extract as an active ingredient. Further, the present specification relates to a composition which contains ginseng berry extract and alleviates premenstrual syndrome and menstrual pain. Further, in the present specification, the composition exhibits the effect of alleviating or improving the symptoms of premenstrual syndrome, and hence can be used as a pharmaceutical composition and food composition.

The invention relates to a medicine composition for relieving symptoms before female menstruation. The medicine composition is prepared from the following raw materials: radix bupleuri, fructus aurantii, cortex albiziae, radix curcumae, rhizoma cyperi, pericarpium citri reticulatae viride, beautiful sweetgum fruit, tangerine seed, angelica, radix paeoniae alba, Szechuan lovage rhizome, poria cocos, pericarpium arecae and liquorice. The medicine composition treats both the symptoms and root causes, is remarkable in treating effect, has a very good effect on treating a premenstrual syndrome, and is broad in application prospect.

The present invention discloses pharmaceutical / nutritional compositions and methods for alleviating symptoms associated with premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD). The pharmaceutical / nutritional compositions include at least 2% (w / w) phosphatidyl-L-serine, or salts thereof, out of a total effective composition, as a first effective ingredient; and a suitable amount of at least one bio-available form of magnesium as a second effective ingredient. Preferably, the bio-available form of magnesium is magnesium oxide, magnesium citrate, magnesium hydroxide, magnesium stearate, or a magnesium salt of the phosphatidyl-L-serine. Preferably, the composition further includes a pharmaceutical or nutritional excipient. Preferably, the total effective composition is administrable in a multi-part regimen. Preferably, the total effective composition is administrable by intravenous or oral delivery. Preferably, the pharmaceutical / nutritional composition further includes at least 2% (w / w) phosphatidic acid, or salts thereof, out of the total effective composition, as a first effective ingredient.

A lighting control system includes: a biological information obtainer which obtains biological information related to a biological body of a user; an environmental information obtainer which obtains environmental information related to a surrounding environment of the user; a severity determiner which determines a severity of premenstrual syndrome (PMS) based on the biological information obtained by the biological information obtainer and the environmental information obtained by the environmental information obtainer; and a lighting controller which controls a lighting device based on the severity determined by the severity determiner.

The present invention discloses pharmaceutical / nutritional compositions for alleviating symptoms associated with premenstrual syndrome (PMS) and methods of treatment for PMS using such pharmaceutical / nutritional composition including: at least 2% (w / w) phosphatidyl-L-serine, or salts thereof, out of a total composition, as an effective ingredient, wherein: the phosphatidyl-L-serine has a structural fatty-acid chain derived from at least one raw material lecithin. Preferably, the phosphatidyl-L-serine is produced by enzymatic reaction of at least one raw material lecithin with phospholipase-D; at least one raw material lecithin is selected from the group consisting of: a vegetal lecithin and a non-vegetal lecithin; and the phospholipase-D is selected from the group consisting of: vegetal phospholipase-D, bacterial-originated enzyme phospholipase-D, and a combination of vegetal phospholipase-D and bacterial-originated enzyme phospholipase-D. Preferably, the structural fatty-acid chain is a saturated, hydrogenated fatty-acid chain. Preferably, the phosphatidyl-L-serine is derived from a dairy lecithin.

The invention relates to a pharmaceutical preparation with functions of activating blood circulation and dredging collaterals as well as an application of the pharmaceutical preparation. The pharmaceutical preparation is prepared from raw materials as follows: Chinese thorowax roots, orange fruits, silktree albizia bark, turmeric root tubers, nutgrass galingale rhizomes, green tangerine peels, beautiful sweetgum fruits, tangerine seeds, Chinese angelica, white peony roots, Szechwan lovage rhizomes, Indian buead, areca peels and liquorice roots. The medicine treats both symptoms and root causes, has the significant curative effect, has the good treatment effect on the premenstrual syndrome and has the broad application prospect.

The invention provides a flavonoid new chemical entity, which has little moisture absorption and good storage stability, and is applicable to preparation of food or health food or drugs for reduction of capillary fragility, treatment or prevention of chronic venous insufficiency, hemorrhoid, scurvy, venous lower limb ulcer, premenstrual syndrome, diabetics' microangiopathy and secondary upper limb lymphedema, cardiovascular diseases, blood glucose and lipid regulation, antisepsis and inflammation reduction, virus resisting, cancer resisting, immunity adjustment, radiation protection, liver protection, rheumatoid arthritis or arthritis resisting, ulcer resisting, phlegm eliminating, asthma relieving, black spots, freckles, free radical resistance, and oxidation resistance.

A bolus dose supplement, foodstuff, beverage and beverage concentrate with calcium and vitamin D for the treatment and prevention of PMS, panic attacks, and postpartum depression. The combination of adequate calcium and vitamin D is provided as a multi-vitamin and mineral supplement. The bolus dose is comprised of 2 main ingredients calcium and vitamin D at 1000-1500 mg of elemental calcium in the form of carbonate or citrate or gluconate or citrate maleate and 400-20,000 I.U. of parent vitamin D

Spiroindoline derivatives, processes for their preparation and pharmaceutical compositions thereof, their use for the treatment of diseases, and their use for the manufacture of medicaments for the treatment of diseases, especially sex-hormone-related diseases in both men and women, in particularly those selected from the group of endometriosis, uterine leiomyoma (fibroids), polycystic ovarian disease, menorrhagia, dysmenorrhea, hirsutism, precocious puberty, gonadal steroid-dependent neoplasia such as cancers of the prostate, breast and ovary, gonadotrope pituitary adenomas, sleep apnea, irritable bowel syndrome, premenstrual syndrome, benign prostatic hypertrophy, contraception, infertility and assisted reproductive therapy such as in vitro fertilization. The present application relates in particular to spiroindoline derivatives as gonadotropin-releasing hormone (GnRH) receptor antagonists.

Premenstrual syndrome (PMS) refers to a group of symptom complex repeatedly occurring 7-14 days before menstruation (namely in a luteal phase of a menstrual cycle), affecting women daily life and work and relating to bodies, spirit and behavior, the symptom disappears naturally after menses, and about 90% of women of child-bearing age are estimated to have at least one PMS. The invention aims to provide a pharmaceutical composition for treating premenstrual tension syndrome and a preparation method thereof. The pharmaceutical composition is composed of radix bupleuri, cape jasmine, malt, radix rhapontied and siphonostegia chinensis. The pharmaceutical composition has the functions of soothing liver and relieving depression, regulating qi to alleviate pain, and promoting blood circulation to regulate menstruation, and is used for liver qi unfavorable prognosis syndrome of the premenstrual tension syndrome. The preparation method of the pharmaceutical composition comprises the steps: extracting and concentrating the pharmaceutical composition with water or an appropriate concentration of ethanol or concentrating after recovery of the ethanol, removing impurities, drying, mixing with suitable auxiliary materials, and preparing a pharmaceutically acceptable preparation.

A gonadotropin-releasing hormone antagonistic composition, which comprises an optionally substituted condensed-bicyclic compound consisting of a homo or hetero 5 to 7 membered ring and a homo or hetero 5 to 7 membered ring is effective as a propylactic or therapeutic agent for the prevention or treatment of several hormone dependent diseases, for example, a sex hormone dependent cancer (e.g. prostatic cancer, cancer of uterine cervix, breast cancer, pituitary adenoma), benign prostatic hypertrophy, myoma of the uterus, endometriosis, precocious puberty, amenorrhea, premenstrual syndrome, pplycystic ovary syndrome and acne vulgaris; is effective as a fertility controlling agent in both sexes (e.g. a pregnancy controlling agent and a menstrual cycle controlling agent); can be used as a contraceptive of male or female, as an ovulation-inducing agent of female; can be used as an infertility treating agent by using a rebound effect owing to a stoppage of administration thereof; is useful as modulating estrous cycles in animals in the field of animal husbandry, as an agent fro improving the quality of edible meat or promoting the growth of animals; is useful as an agent of spawning promotion in fish.

The invention relates to a premenstrual calming tablet and a preparation process thereof. The preparation is mainly prepared from the following raw materials: radix bupleuri, fructus aurantii, rhizoma zingiberis, radix curcumae, rhizoma cyperi, pericarpium citri reticulatae viride, liquidambar formosana hance, tangerine seed, Chinese angelica, white paeony root, ligusticum wallichii, poria cocos, pericarpium arecae, liquorice and the like which are prepared into the tablet according to the normal method. Based on the prior art, the premenstrual calming tablet is applied according to syndrome, and the components of the traditional Chinese medicines are matched with each other to coordinate efficiency, so that the premenstrual calming tablet is low in cost, good in treatment effect in premenstrual syndrome according to the clinical verification, and wide in application prospect.

A composition is disclosed for alleviating or managing symptoms associated with premenstrual syndrome "PMS" comprising an effective amount of an aqueous mixture of water and a rapidly digestible carbohydrate blend. The aqueous mixture is essentially free of protein and is characterized by a certain pH and ratio of water to carbohydrate blend. Methods of use of the composition for alleviating or managing symptoms associated with PMS are also disclosed.